Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jander, S.
Right arrow Articles by Stoll, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jander, S.
Right arrow Articles by Stoll, G.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Myasthenia

Neurology 2002;59:287-289
© 2002 American Academy of Neurology
Brief Communications

Increased serum levels of the interferon-{gamma}–inducing cytokine interleukin-18 in myasthenia gravis

Sebastian Jander, MD and Guido Stoll, MD

From the Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany.

Address correspondence and reprint requests to Dr. Sebastian Jander, Department of Neurology, Heinrich-Heine-University, Moorenstr. 5, D-40225 Düsseldorf, Germany; e-mail: jander{at}uni-duesseldorf.de

In this study, the authors show that MG as an autoantibody-mediated disorder of neuromuscular transmission is associated with elevated serum levels of the interferon-{gamma}–inducing cytokine interleukin (IL)-18. IL-18 levels were higher in generalized than in ocular myasthenia and tended to decrease on clinical improvement. These findings suggest an unexpected role of IL-18 in B-cell–mediated autoimmune disease.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
H. Yang, E. Tuzun, D. Alagappan, X. Yu, B. G. Scott, A. Ischenko, and P. Christadoss
IL-1 Receptor Antagonist-Mediated Therapeutic Effect in Murine Myasthenia Gravis Is Associated with Suppressed Serum Proinflammatory Cytokines, C3, and Anti-Acetylcholine Receptor IgG1
J. Immunol., August 1, 2005; 175(3): 2018 - 2025.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Poea-Guyon, P. Christadoss, R. Le Panse, T. Guyon, M. De Baets, A. Wakkach, J. Bidault, S. Tzartos, and S. Berrih-Aknin
Effects of Cytokines on Acetylcholine Receptor Expression: Implications for Myasthenia Gravis
J. Immunol., May 15, 2005; 174(10): 5941 - 5949.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.